Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as experimental vaccine
Low-dose experimental vaccine · 1 trial · 2 indications
The incidence of adverse reactions within 0\~30 days after each dose vaccination.
The seroconversion rate of gE antibody on Day 30 after two doses vaccination.
The GMC of gE antibody on Day 30 after two doses vaccination.
| Arm | Type | Description |
|---|---|---|
| Low-dose group | EXPERIMENTAL | Participants will receive two doses of lyophilized herpes zoster virus mRNA vaccine (low dosage), with 30 days or 60 days apart |
| High-dose group | EXPERIMENTAL | Participants will receive two doses of lyophilized herpes zoster virus mRNA vaccine (high dosage), with 30 days or 60 days apart |
| Comparator A | ACTIVE_COMPARATOR | Participants will receive a single dose of saline on day 0 and a single dose of herpes zoster vaccine, live on day 60 |
| Comparator B | ACTIVE_COMPARATOR | Participants will receive two doses of recombinant zoster vaccine (CHO cell), with 60 days apart |
| Comparator C | PLACEBO_COMPARATOR | Participants will receive two doses of saline, with 60 days apart |
| Name | Type | Description |
|---|---|---|
| Low-dose experimental vaccine | BIOLOGICAL | Lyophilized herpes zoster virus mRNA vaccine |
| High-dose experimental vaccine | BIOLOGICAL | Lyophilized herpes zoster virus mRNA vaccine |
| Active-controlled vaccine A | BIOLOGICAL | herpes zoster attenuated live vaccine, lyophilized |
| Active-controlled vaccine B | BIOLOGICAL | Shingrix® |
| Placebo group | OTHER | Saline |
Inclusion Criteria: * Phase I: Age ≥ 40 years; Phase II: Age ≥ 50 years; * Participants are able to understand and voluntarily sign the informed consent form; * Able to provide legal identification; * Participants of childbearing potential and their sexual partners agree to voluntarily adopt effect...
The Experimental vaccine is an investigational vaccine being developed for the prevention of Epidemic Meningitis, specifically meningococcal disease caused by groups A, C, Y, and W135. It is also being studied for use in Poliomyelitis and Herpes Zoster, though its primary clinical trials focus on meningococcal conjugate vaccination in children.
The Experimental vaccine is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company traded on the NASDAQ under the ticker symbol SVA. The company is conducting Phase 3 clinical trials for this vaccine candidate in China.
The Experimental vaccine is currently in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities. All four of its registered clinical trials are Phase 3 studies, with three actively recruiting participants and one active but not recruiting.
The Experimental vaccine is being evaluated in four Phase 3 clinical trials in China, all studying its use against Epidemic Meningitis. These trials are NCT07505810 (children aged 3-5 months), NCT07505823 (children aged 6-11 months), NCT07505836 (children aged 12-23 months), and NCT07505888 (children aged 2-6 years).
Yes, the Experimental vaccine is also known as the Low-dose experimental vaccine. This alternative name may be used in some contexts to refer to the same vaccine candidate being developed by Sinovac Biotech for meningococcal disease prevention.
The Experimental vaccine is a meningococcal conjugate vaccine designed to protect against Neisseria meningitidis serogroups A, C, Y, and W135. By presenting these bacterial antigens to the immune system, it stimulates the production of protective antibodies that can prevent meningococcal infection and the associated epidemic meningitis.